Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
Jurjen Tel,Erik H.J.G. Aarntzen,Tetsuro Baba,Gerty Schreibelt,Barbara M. Schulte,Daniel Benitez-Ribas,Otto C. Boerman,Sandra Croockewit,Wim J.G. Oyen,Michelle M. van Rossum,Gregor Winkels,Pierre Coulie,Cornelis J. A. Punt,Carl G. Figdor,I. Jolanda M. de Vries +14 more
TLDR
The results indicate that vaccination with naturally occurring pDC is feasible with minimal toxicity and that in patients with metastatic melanoma, it induces favorable immune responses.Abstract:
Vaccination against cancer by using dendritic cells has for more than a decade been based on dendritic cells generated ex vivo from monocytes or CD34(+) progenitors. Here, we report on the first clinical study of therapeutic vaccination against cancer using naturally occurring plasmacytoid dendritic cells (pDC). Fifteen patients with metastatic melanoma received intranodal injections of pDCs activated and loaded with tumor antigen-associated peptides ex vivo. In vivo imaging showed that administered pDCs migrated and distributed over multiple lymph nodes. Several patients mounted antivaccine CD4(+) and CD8(+) T-cell responses. Despite the limited number of administered pDCs, an IFN signature was observed after each vaccination. These results indicate that vaccination with naturally occurring pDC is feasible with minimal toxicity and that in patients with metastatic melanoma, it induces favorable immune responses.read more
Citations
More filters
Journal ArticleDOI
Cancer immunotherapy via dendritic cells
TL;DR: Dendritic cells are an essential target in efforts to generate therapeutic immunity against cancer owing to their ability to control both immune tolerance and immunity.
Journal ArticleDOI
Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.
Alexandra-Chloé Villani,Alexandra-Chloé Villani,Rahul Satija,Rahul Satija,Gary Reynolds,Siranush Sarkizova,Karthik Shekhar,James Fletcher,Morgane Griesbeck,Andrew Butler,Shiwei Zheng,Suzan Lazo,Laura Jardine,David Dixon,Emily Stephenson,Emil Nilsson,Ida Grundberg,David McDonald,Andrew Filby,Weibo Li,Weibo Li,Philip L. De Jager,Philip L. De Jager,Orit Rozenblatt-Rosen,Andrew A. Lane,Andrew A. Lane,Muzlifah Haniffa,Muzlifah Haniffa,Aviv Regev,Aviv Regev,Aviv Regev,Nir Hacohen,Nir Hacohen +32 more
TL;DR: This refined analysis has identified, among others, a previously unknown dendritic cell population that potently activates T cells and reclassify pDCs as the originally described “natural interferon-producing cells (IPCs)” with weaker T cell proliferation induction ability.
Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors
Alexandra-Chloé Villani,Alexandra-Chloé Villani,Rahul Satija,Rahul Satija,Gary Reynolds,Siranush Sarkizova,Karthik Shekhar,James Fletcher,Morgane Griesbeck,Andrew Butler,Shiwei Zheng,Suzan Lazo,Laura Jardine,David Dixon,Emily Stephenson,Emil Nilsson,Ida Grundberg,David McDonald,Andrew Filby,Weibo Li,Weibo Li,Philip L. De Jager,Philip L. De Jager,Orit Rozenblatt-Rosen,Andrew A. Lane,Andrew A. Lane,Muzlifah Haniffa,Muzlifah Haniffa,Aviv Regev,Aviv Regev,Aviv Regev,Nir Hacohen,Nir Hacohen +32 more
TL;DR: In this paper, the authors performed single-cell RNA sequencing of ~2400 cells isolated from healthy blood donors and enriched for HLA-DR + lineage − cells, which led them to identify and validate six Dendritic cells (DCs) and four monocyte subtypes.
Journal ArticleDOI
Dendritic cells in cancer immunology and immunotherapy.
Stefanie K. Wculek,Francisco J. Cueto,Adriana M. Mujal,Ignacio Melero,Matthew F. Krummel,David Sancho +5 more
TL;DR: How different DC subsets influence immunity and tolerance in cancer settings is outlined and the implications for both established cancer treatments and novel immunotherapy strategies are discussed.
Journal ArticleDOI
The multifaceted biology of plasmacytoid dendritic cells
Melissa Swiecki,Marco Colonna +1 more
TL;DR: Recent progress in the field of pDC biology is summarized, focusing on the molecular mechanisms that regulate the development and functions of p DCs, the pathways involved in their sensing of pathogens and endogenous nucleic acids, their functions at mucosal sites, and their roles in infection, autoimmunity and cancer.
References
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
TL;DR: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Journal ArticleDOI
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch,Jeffrey E. Gershenwald,Seng-Jaw Soong,John F. Thompson,Michael B. Atkins,David R. Byrd,Antonio C. Buzaid,Alistair J. Cochran,Daniel G. Coit,Shouluan Ding,Alexander M.M. Eggermont,Keith T. Flaherty,Phyllis A. Gimotty,John M. Kirkwood,Kelly M. McMasters,Martin C. Mihm,Donald L. Morton,Merrick I. Ross,Arthur J. Sober,Vernon K. Sondak +19 more
TL;DR: Revised melanoma staging system has been made that reflect the improved understanding of this disease and will be formally incorporated into the seventh edition of the AJCC Cancer Staging Manual and implemented by early 2010.
Journal ArticleDOI
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert,Luc Thomas,Igor Bondarenko,Steven J. O'Day,Jeffrey S. Weber,Claus Garbe,Céleste Lebbé,Jean Francois Baurain,Alessandro Testori,Jean-Jacques Grob,Neville Davidson,Jon M. Richards,Michele Maio,Axel Hauschild,Wilson H. Miller,Pere Gascón,Michal Lotem,Kaan Harmankaya,Ramy Ibrahim,Stephen Francis,Tai-Tsang Chen,R. Humphrey,Axel Hoos,Jedd D. Wolchok +23 more
TL;DR: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Journal ArticleDOI
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Charles M. Balch,Antonio C. Buzaid,Seng Jaw Soong,Michael B. Atkins,Natale Cascinelli,Daniel G. Coit,Irvin D. Fleming,Jeffrey E. Gershenwald,Alan Houghton,John M. Kirkwood,Kelly M. McMasters,Martin F. Mihm,Donald L. Morton,Douglas S. Reintgen,M. I. Ross,Arthur J. Sober,John A. Thompson,John F. Thompson +17 more
TL;DR: This revision of the staging system for cutaneous melanoma will become official with publication of the sixth edition of the AJCC Cancer Staging Manual in the year 2002.